Endure Biotherapeutics, Inc.
Endure Bio is focused on engineering therapeutic strains of native bacteria that persist in the body, aiming to treat and potentially cure a range of genetic and chronic diseases through their innovative platform of engineered native bacteria. Their approach involves isolating native bacteria, genetically engineering them to deliver therapeutic proteins, and reintroducing them as oral capsules to engraft and colonize the gut for long-term benefits.
Industries
Nr. of Employees
small (1-50)
Endure Biotherapeutics, Inc.
Products
Engrafting live bacterial therapeutic candidates (oral capsules)
Engineered native gut bacterial strains formulated as freeze-dried oral capsules designed to engraft in the gastrointestinal tract and deliver therapeutic transgenes over extended periods.
Engrafting live bacterial therapeutic candidates (oral capsules)
Engineered native gut bacterial strains formulated as freeze-dried oral capsules designed to engraft in the gastrointestinal tract and deliver therapeutic transgenes over extended periods.
Services
Collaborative research and partnership engagements to develop or translate engineered native bacterial therapeutics, including outreach for investment and technology partnerships.
Collaborative research and partnership engagements to develop or translate engineered native bacterial therapeutics, including outreach for investment and technology partnerships.
Expertise Areas
- Live biotherapeutics development
- Microbiome engineering
- Bacterial strain genetic engineering
- Transgene delivery using native bacterial chassis
Key Technologies
- Genetic modification of native gut bacteria
- Native bacterial chassis (E. coli) for transgene delivery
- Expression of bacterial enzymes and eukaryotic cytokines in bacteria
- Lyophilization and oral capsule formulation of live biotherapeutics
News & Updates
A recent publication emphasizing the role of gut microbial bile acid modulation in digestive health.
Endure Bio® was accepted into the California Life Sciences FAST Fall Cohort.
A scientific publication detailing the company's technology.
Endure Bio received the Cool Company status from CONNECT.
Endure Bio was awarded Cool Company status by CONNECT in April 2022.
A recent publication emphasizing the role of gut microbial bile acid modulation in digestive health.
Endure Bio® was accepted into the California Life Sciences FAST Fall Cohort.
A scientific publication detailing the company's technology.
Endure Bio received the Cool Company status from CONNECT.
Endure Bio was awarded Cool Company status by CONNECT in April 2022.